15 September 2009  Two become one: QED Integration increases operational strength

QED Clinical Services has recently joined forces with QED Partnership, another highly experienced UK based CRO. The coming together of the two companies under the QED Clinical Services umbrella means that the merged organization can now provide further expertise, capacity and enhanced quality in the conduct of clinical trials. The two companies were already long term partners, sharing many similarities and hence this is a highly complementary pairing. The resulting enhanced QED Clinical Services organization can now draw on the vast experience of new Senior Management team members, such as Susan Ollier, BSc, MRQA, HonFICR, CSci and David Ollier BSc, MICR. Susan was previously the chair of the Institute of Clinical Research (ICR) for 2 years and a member of the ICR Board for 6 years and David has an extensive clinical background with focus on working closely with the NHS. The QED Partnership team also bring a diverse customer base ranging from large pharmaceutical sponsors to small Biotech which complement the numerous existing QED Clinical sponsors. Furthermore the team possess a wealth of experience in Research Governance, Auditing and Training within the NHS which will allow QED Clinical Services to expand its non-commercial sponsor business significantly.

09 September 2009  Best CRO 2009: QED Clinical Services Shortlisted

QED Clinical Services is proud to announce that it has been shortlisted in the category of “Best CRO” in the 5th Annual Scrip awards. This competition, organized by Scrip World Pharmaceutical News, a major provider of news and analysis for the global biopharmaceutical industry, promotes new standards of excellence and celebrates achievements that reflect the innovating nature of the industry. QED has been nominated alongside several leading global CROs by an illustrious panel of pharmaceutical industry experts.
Scrip’s Best CRO Award is given in recognition of the key role CROs play in drug development. QED are confident that their success in building trust and solid working relationships, and its development as a highly innovative and flexible organisation, make it a crucial CRO partner for the pharmaceutical industry.

01 September 2009  QED extends offering to Safety and Pharmacovigilance Services

Demonstrating their appreciation of the critical importance of safety and pharmacovigilance in clinical trials, not just from a Regulatory standpoint, QED Clinical Services has extended its service offering to include provision of extensive Safety and PV services, ranging from SAE & SUSAR reporting through to consultancy and training. QED’s expert Safety team can provide a centralized and highly coordinated service for global studies as well as drawing on local expertise on a country-by-country basis. Similarly to their wider service offering, QED are able to tailor their safety and PV service provision to each individual client ranging from handling high volumes of SAEs for large pharma sponsors through to acting as a complete Safety Department for smaller Biotech sponsors. QED’s Safety/PV team consists of highly experienced Senior Pharmacovigilance Specialists with on average more than 10 years industry experience.

01 July 2009   QED awarded Phase II haematology trial

QED has been awarded a multinational Phase II clinical trial with polyclonal antibodies in patients with Idiopathic Thrombocytopenic Purpura (ITP).

ITP is an autoimmune bleeding disorder characterized by abnormally low platelet levels, making it difficult for the blood to clot normally. It is a chronic and debilitating disease, associated with increased bleeding risk and impaired quality of life.

Thomas Ogorka, Managing Director of QED said “We are very pleased to assist the Sponsor with this challenging study in a rare disease such as ITP. The success of this study will be directly linked with the selection of high quality Investigators and of course our experienced study team”.

Back to top